GMP compliant facility has clinical and commercial manufacturing capabilities to support the company's growing pipeline of targeted alpha therapies (TATs).
Despite FDA's postponement of most facility inspections, the pharma manufacturing industry should be prepared for heightened scrutiny as this crisis develops.
John J. Carney, Lee H. Rosebush, Susrut A. Carpenter, Andrew M. Serrao, BakerHostetler04.22.20